格隆汇1月15日丨康龙化成(03759.HK)发布公告，2026年1月14日，公司与配售代理(即高盛与汇丰)订立 配售协议，据此，各配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并尽力促使承配人 按配售协议所载的条款及条件，以每股配售股份的配售价格认购总计5844.08万股新H股。 配售所得款项净额预期约为13.19亿港元，并将按以下方式动用：约70%将用于公司的项目建设，以加 强本公司实验室服务设施、药物工艺开发及生产设施的能力及产能；约10%将用于偿还银行贷款及其他 借款，以优化公司的资本结构；及约20%将用于补充营运资金及作其他一般公司用途。上述募集资金用 途届时会根据最终的发行规模进行相应调整。 配售股份数目分别占截至本公告日期现有已发行H股总数及现有已发行股份总数约19.86%和3.30%。配 售价每股配售股份港币22.82元，较1月14日(即配售协议签署的最后交易日)香港联交所所报收市价每股 H股港币24.94元折价约8.50%。配售股份将根据一般发行授权发行。 ...

Group 1 - The company, Litian Film Industry (09958), plans to place up to 72 million shares at a price of HKD 0.20 per share, targeting at least six subscribers [1] - If all placement shares are fully subscribed, the net proceeds are expected to be approximately HKD 14 million, which will be used for the company's general working capital [1]

Core Viewpoint - The company,药捷安康-B (02617.HK), has announced a placement agreement with CITIC Securities to issue 2.1 million shares at a price of HKD 92.85 per share, representing a discount of approximately 17.98% from the closing price of HKD 113.20 on January 13 [1] Group 1 - The placement shares represent about 0.70% of the existing issued H shares and 0.53% of the total issued shares as of the announcement date [1] - The expected total gross proceeds from the placement are approximately HKD 194.99 million, with net proceeds estimated at around HKD 190.14 million [1] Group 2 - The company plans to allocate approximately 60% of the net proceeds to fund clinical trials for its core product, Tinengotinib, in treating cholangiocarcinoma (CCA) and other indications [1] - About 30% of the net proceeds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1] - The remaining 10% of the net proceeds will be allocated for working capital and general corporate purposes [1]

格隆汇1月12日丨璋利国际(01693.HK)公告，于2026年1月12日，公司与配售代理订立配售协议，据此， 配售代理有条件同意按尽力基准促使以每股配售股份2.20港元的价格向目前预期的不少于六(6)名承配人 配售最多361万股配售股份。配售事项须待(其中包括)上市委员会批准配售股份上市及买卖後，方可作 实。配售价为每股配售股份2.20港元较最后交易日在联交所所报收市价每股2.25港元折让约2.22%。 假设配售股份获悉数配售，则配售事项的最高所得款项总额预期将为794万港元，及配售事项所得款项 净额(经扣除所有适用成本及开支，包括配售佣金及徵费)将约为769万港元，即每股配售股份之净价约 为2.13港元。公司拟将配售事项所得款项净额用作集团的一般营运资金(包括员工薪酬、专业费用及其 他营运开支)。 ...

Group 1 - The core viewpoint of the article is that 恒昌集团国际 (Hengchang Group International) is undergoing a share placement process, with a significant portion of its shares being transferred and a new share placement agreement established [1] Group 2 - On January 9, 恒昌集团国际's shareholders transferred shares worth HKD 5.4846 million to 日发证券 (Rifa Securities), representing 7.39% of the company [1] - The company has entered into a placement agreement on January 6, 2026, with the placement agent agreeing to facilitate the subscription of up to 33.365 million shares at a price of HKD 0.34 per share, which is a discount of approximately 19.05% from the market price of HKD 0.42 at the time of the agreement [1] - If all placement shares are subscribed, the total proceeds from the placement are expected to be approximately HKD 11.34 million, with a net amount of about HKD 10.54 million, resulting in a net issue price of approximately HKD 0.32 per share, which will be used for general working capital [1]

Group 1 - The core viewpoint of the article is that 恒昌集团国际 (Hengchang Group International) is undergoing a stock transfer and a share placement to raise funds for general operational purposes [1] Group 2 - On January 9, 恒昌集团国际's shareholders transferred stocks worth HKD 5.4846 million from China Galaxy Securities Hong Kong to 日发证券 (Rifa Securities), representing 7.39% of the total shares [1] - The company announced a placement agreement on January 6, 2026, with a placement agent to facilitate the subscription of up to 33.365 million shares at a price of HKD 0.34 per share, which is a discount of approximately 19.05% compared to the closing price of HKD 0.42 on the agreement date [1] - If all placement shares are subscribed, the total proceeds from the placement are expected to be approximately HKD 11.34 million, with a net amount of about HKD 10.54 million, resulting in a net issue price of approximately HKD 0.32 per share [1] - The net proceeds from the placement are intended to be used entirely for the company's general working capital [1]

Core Viewpoint - Easy Life Holdings (00223) announced a placement agreement to issue up to 271 million new shares at a price of HKD 0.102 per share, representing a discount of approximately 17.07% from the closing price of HKD 0.123 on the date of the agreement [1] Group 1 - The placement will be made to no fewer than six subscribers and is subject to the general authority granted to the directors at a special shareholders' meeting [1] - The maximum number of shares to be placed represents about 16.67% of the total issued share capital after the placement [1] - The total nominal value of the maximum number of shares to be placed is approximately HKD 27.12 million [1] Group 2 - If all placement shares are successfully placed, the estimated total gross proceeds from the placement will be approximately HKD 27.66 million, with a net amount of about HKD 27.13 million [1] - The proceeds are intended to be used for the development of the group's supply chain business, repayment of certain outstanding payables (including professional fees and loan repayments), and to supplement the group's working capital [1]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」或「香港聯交所」）及香港中央結算有限公司（「香 港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 除非本公告另有界定，否則本公告所用詞彙與豪威集成電路（集團）股份有限公司（「本公司」）日期為2025年12月31 日的招股章程（「招股章程」）所界定者具有相同涵義。本公告乃承本公司董事（「董事」）會（「董事會」）之命而作出。 董事會就本公告之準確性共同及個別承擔責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。潛在投資者在決定 是否投資於發售股份前，應細閱招股章程以了解下文所述有關全球發售的詳細資料。投資者應僅依賴招股章程所 載資料作出有關發售股份的任何投資決定。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區或法律禁止此類發佈的任何 其他司法權區）發佈、刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法權區購買或認購證券的任 何要約或招攬的一部分。本公告所述證券 ...

Group 1 - The company, Guangjun Group Holdings (08516), announced that there are no excluded shareholders as of the record date, resulting in no unqualified shareholders failing to sell their rights issue shares [1] - As of the deadline on January 2, 2026, the company received a total of 8 valid applications for a total of 19.6352 million rights issue shares, which represents approximately 47.8% of the total shares offered under the rights issue [1] - The remaining 21.4708 million shares, which were not subscribed, account for about 52.2% of the total shares offered under the rights issue and will be disposed of according to the compensation arrangement [1] Group 2 - The company has made arrangements to sell the 21.4708 million unsubscribed rights issue shares to independent underwriters, as per GEM Listing Rule 10.31(1)(b), to benefit shareholders who participated in the rights issue [1] - A placement agreement was established with the placement agent on May 23, 2025, regarding the placement of the unsubscribed shares during the placement period, with any premium generated above the subscription price to be proportionately paid to non-action shareholders [1] - The placement agent will endeavor to facilitate the subscription of all (or as many as possible) unsubscribed rights issue shares between January 9, 2026, and no later than January 12, 2026 [1]

Core Viewpoint - 恒昌集团国际 (01421) has announced a placement agreement to issue up to 33.365 million shares at a price of HKD 0.34 per share, representing a discount of approximately 19.05% from the market price on the agreement date [1] Group 1 - The placement will increase the total issued share capital by approximately 16.67% [1] - If fully subscribed, the total proceeds from the placement are expected to be around HKD 11.34 million, with a net amount of approximately HKD 10.54 million [1] - The net issue price per share is expected to be around HKD 0.32 [1] Group 2 - The company intends to use the net proceeds from the placement for general working capital [1]